Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer in the Elderly

Journal of Clinical Oncology, 04/26/2012

Uptake of adjuvant chemotherapy for non–small–cell lung cancer (NSCLC) increased in patients age 70years or older following reporting of pivotal adjuvant chemotherapy trials, but it remained below that for patients younger than age 70years. Adoption of adjuvant chemotherapy appears to be associated with significant survival benefit in the elderly (age ≥70years), with tolerability apparently similar to that of patients who are younger than age 70years.

Print Article Summary Cat 2 CME Report